Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio sull'efficacia e sulla sicurezza di GNR-068 (Ustekinumab biosimilare) e Stelara® nel trattamento di pazienti con psoriasi a placche da moderata a grave

16 settembre 2026 aggiornato da: AO GENERIUM

Studio clinico comparativo randomizzato in cieco multicentrico internazionale sull'efficacia e la sicurezza di GNR-068 (45 mg) e Stelara® (45 mg) e valutazione della sicurezza, tollerabilità ed efficacia a lungo termine di GNR-068 in pazienti con malattia moderata e Forme gravi di psoriasi a placche

This is a randomized single-blind comparative parallel group efficacy and safety study of ustekinumab biosimilar GNR-068 (45 mg) and reference product Stelara® (45 mg) in the treatment of patients with moderate and severe forms of plaque psoriasis. Participants received a subcutaneous dose of ustekinumab 45 mg (GNR-068 or Stelara®) at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg. For patients with partially respond to the initial regimen the regimen can be adjusted.

Panoramica dello studio

Stato

Completato

Condizioni

Descrizione dettagliata

The drug GNR-068 (INN: ustekinumab) is being developed as a biosimilar to the drug Stelara®, solution for subcutaneous administration (Silag AG, Switzerland).

Preclinical studies and early phase clinical studies suggest that interleukins-12 (IL-12) and -23 (IL-23), two molecules that are part of the communication network in the immune system, may play an important role in psoriasis. Ustekinumab is a monoclonal antibody directed against IL-12 and IL-23. This is a randomized, single blind, parallel-group, multicenter study to determine the effectiveness and safety of ustekinumab biosimilar GNR-068 administered subcutaneously as compared with Stelara® in patients with moderate to severe plaque-type psoriasis. Patients receive GNR-068 45 mg or Stelara 45 mg administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28, thereafter until week 52 all patients receive GNR-068. For patients who partially respond to the initial regimen, the dose can be adjusted to 90 mg and then the interval can be adjusted to every 8 weeks. The study included a screening period, comparative treatment period, non-comparative treatment period, follow up period. Allocation of patients to treatment groups was carried out by randomization in a ratio of 1:1. 422 patients (211 to each study groups) were randomized.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

422

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Barnaul
      • Barnaul, Barnaul, Russia, 656038
        • Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation
    • Chelyabinsk Oblast
      • Chelyabinsk, Chelyabinsk Oblast, Russia, 454048
        • State budgetary healthcare institution "Chelyabinsk Regional Clinical Dermatovenerological Dispensary"
      • Chelyabinsk, Chelyabinsk Oblast, Russia, 454126
        • Limited Liability Company "Ecology of Health"
    • Ekaterinburg
      • Yekaterinburg, Ekaterinburg, Russia, 620076
        • State budgetary institution of the Sverdlovsk region "Ural Research Institute of Dermatovenereology and Immunopathology"
    • Izhevsk
      • Izhevsk, Izhevsk, Russia, 426061
        • Limited Liability Company "Alliance Biomedical - Ural Group"
    • Kirov Oblast
      • Kirov, Kirov Oblast, Russia, 610027
        • Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Health of the Russian Federation (FSBEI HE Kirov State Medical University of the Ministry of Health of Russia))
    • Leningradskaya Oblast'
      • Murino, Leningradskaya Oblast', Russia, 188678
        • Limited Liability Company "Available Polyclinic"
    • Lipetsk Oblast
      • Lipetsk, Lipetsk Oblast, Russia, 398005
        • State health care institution "Regional Dermatovenerological Dispensary"
    • Moscow
      • Moscow, Moscow, Russia, 105554
        • Limited Liability Company "OLLA-MED"
      • Moscow, Moscow, Russia, 115522
        • Federal State Budgetary Institution "Research Institute of Rheumatology named after V.A. Nasonova"
      • Moscow, Moscow, Russia, 117321
        • Limited Liability Company "Firma ORIS"
      • Moscow, Moscow, Russia, 119071
        • State budgetary healthcare institution of the city of Moscow "Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow Health Department"
      • Moscow, Moscow, Russia, 127006
        • Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation (FSBEI HE "Russian University of Medicine" of the Ministry of Health of Russia)
      • Moscow, Moscow, Russia, 129110
        • State budgetary healthcare institution of the Moscow region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"
    • Moscow Oblast
      • Korolyov, Moscow Oblast, Russia, 141060
        • Limited Liability Company "Family Clinic No. 4"
    • Novosibirsk Oblast
      • Novosibirsk, Novosibirsk Oblast, Russia, 630099
        • Limited Liability Company "Medical Center "Healthy Family"
    • Orenburg Oblast
      • Orenburg, Orenburg Oblast, Russia, 460018
        • Federal State Budgetary Educational Institution of Higher Education Orenburg State Medical University of the Ministry of Health of Russia
    • Ryazan Oblast
      • Ryazan, Ryazan Oblast, Russia, 390046
        • State budgetary institution of the Ryazan region "Regional clinical dermatovenerological dispensary"
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Russia, 191123
        • Limited Liability Company "Clinic of Skin Diseases Pierre Wolkenstein"
      • Saint Petersburg, Sankt-Peterburg, Russia, 191123
        • Limited Liability Company "International Medical Center"
      • Saint Petersburg, Sankt-Peterburg, Russia, 192148
        • Limited Liability Company "Medical Technologies" LLC "Medical Technologies"
      • Saint Petersburg, Sankt-Peterburg, Russia, 194156
        • Limited Liability Company "Health Energy"
      • Saint Petersburg, Sankt-Peterburg, Russia, 194214
        • Limited Liability Company "Interleukin"
      • Saint Petersburg, Sankt-Peterburg, Russia, 196084
        • Limited Liability Company "Institute of Medical Research"
      • Saint Petersburg, Sankt-Peterburg, Russia, 196143
        • Limited Liability Company "Research Center Eco-Safety"
      • Saint Petersburg, Sankt-Peterburg, Russia, 196158
        • Limited Liability Company "PiterKlinika"
      • Saint Petersburg, Sankt-Peterburg, Russia, 196191
        • Limited Liability Company "ArsVite North-West"
      • Saint Petersburg, Sankt-Peterburg, Russia, 196240
        • Limited Liability Company "Curator"
      • Saint Petersburg, Sankt-Peterburg, Russia, 196603
        • Private medical institution "Euromedservice"
      • Saint Petersburg, Sankt-Peterburg, Russia, 197136
        • Limited Liability Company "MEDINET"
    • Saratov Oblast
      • Saratov, Saratov Oblast, Russia, 410012
        • Limited Liability Company "SB Clinic of Cosmetology"
    • Smolensk Oblast
      • Smolensk, Smolensk Oblast, Russia, 214031
        • Regional state budgetary healthcare institution "Smolensk Dermatovenerological Dispensary"
    • Tatarstan Republic
      • Kazan', Tatarstan Republic, Russia, 420111
        • Limited Liability Company Medical Center "Azbuka Health"
    • Ulyanovsk Oblast
      • Ulyanovsk, Ulyanovsk Oblast, Russia, 432063
        • State Budgetary Healthcare Institution Ulyanovsk area Clinical Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Written informed consent to participate in the study.

  • Men and women 18-75 years of age, inclusive, at the time of signing the informed consent form.

  • Patients diagnosed with plaque psoriasis at least 6 months before screening:

    1. Moderate or severe form of the disease, which is defined as: PASI index ≥12, body surface area (BSA) affected by plaque psoriasis, ≥10%, PGA scale score ≥3 (on a scale from 0 to 4).
    2. Presence of indications for systemic therapy, defined as inadequate control of the disease against the background of: local treatment (including local glucocorticosteroids) and/or phototherapy and/or lack of clinical effect from the use of other systemic methods.
    3. It is acceptable to carry out basic therapy for psoriatic arthritis at a stable dose for ≥ 4 weeks before screening: prednisolone at a dose of ≤10 mg per day, NSAIDs, methotrexate at a dose of ≤15 mg per week, sulfasalazine at a dose of 2.0 g per day.
  • Body weight less than 100 kg.

  • If it is necessary to take drugs that worsen the course of psoriasis (beta blockers, calcium channel blockers, lithium drugs, etc.): a stable dose of these drugs for ≥ 4 weeks before randomization.

  • Consent of women of childbearing age, women in menopause lasting less than 2 years and male patients to comply with adequate methods of contraception throughout the study and for 3 months after the end of ustekinumab therapy.

  • Patients should not be donors of blood or its components 30 days before inclusion in the study and not become donors of blood or its components throughout the study and for 3 months after its completion.

Exclusion Criteria:

  • Types of psoriasis other than plaque, except for concomitant psoriatic arthritis.
  • History of therapy with ustekinumab or any therapy aimed at IL-12 or IL-23 (briakinumab, guselkumab, tildrakizumab).
  • Therapy with TNF-alpha inhibitors or any other genetically engineered biological drugs within 3 months before randomization.
  • Conducting other systemic therapies (including cyclosporine, acitretin, methotrexate, UV and PUVA therapy) within 1 month before randomization.
  • Treatment with leflunomide for 6 months before randomization.
  • Spread of the inflammatory process involving the gastrointestinal tract (inflammatory bowel diseases), the organ of vision (uveitis, iridocyclitis), musculoskeletal structures (high activity of psoriatic arthritis, osteoarthritis, uncontrolled against the background of basic therapy (clause 3 Inclusion criteria) ).
  • Major surgery (including joint surgery) within 8 weeks before the start of the study or elective surgery within 6 months after the start of the study.
  • A history of an adverse drug reaction to any of the components of the study drug or a reference drug.
  • Immunization with any live or live attenuated vaccine within 1 month before the first dose of the study drug or comparator drug.
  • A history of a disease associated with the accumulation of immune complexes that may distort the assessment of the effectiveness of ustekinumab therapy (including serum sickness, systemic lupus erythematosus, rheumatoid arthritis, polymyositis, scleroderma, Sjogren's syndrome, vasculitis, cryoglobulinemia).
  • Concomitant diseases and conditions that, in the opinion of the Investigator and/or Sponsor, jeopardize the safety of the patient during participation in the study, or which will influence the analysis of safety data.
  • Active systemic infection (bacterial, viral or fungal) within 14 days before signing the informed consent.
  • Pregnancy or breastfeeding.
  • History of tuberculosis, positive/doubtful result of screening for tuberculosis infection (tuberculosis allergen test or IGRA test or fluorography results). Inclusion of such patients is possible if effective specific treatment for tuberculosis infection has been carried out and there is a conclusion from a phthisiatrician about the possibility of ustekinumab therapy.
  • Participation in clinical trials of drugs less than 5 half-lives of the study drug before signing the informed consent.
  • Positive test for hepatitis B or C, HIV or syphilis.
  • Unwillingness or inability to comply with the recommendations prescribed by this protocol.
  • Identification during screening of other diseases/conditions not listed above that, in the opinion of the physician-researcher, prevent the inclusion of the patient in the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: GNR-068 (JSC "GENERIUM", Russia)

Test drug

GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.

Altri nomi:
  • ustekinumab biosimilare
Comparatore attivo: Stelara® (manufacturer Silag AG, Switzerland)

reference drug

Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.

Altri nomi:
  • ustekinumab

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The proportion of subjects with Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above
Lasso di tempo: Week 12

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The proportion of patients achieving PASI50/75/90/100
Lasso di tempo: Week 60

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 60
Time to reach PASI50, PASI75, PASI90, PASI100
Lasso di tempo: Week 60

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 60
Area under the curve (AUC) of PASI
Lasso di tempo: Week 60

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 60
The proportion of partial responders (ie, patients achieving ≥50% but <75% improvement in PASI compared to baseline)
Lasso di tempo: Week 60

PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).

Week 60
Changes in the BSA index
Lasso di tempo: Week 60

Using the BSA (Body Surface Area) index, the surface area of the skin affected by psoriasis is assessed. BSA is measured in %. To determine the area of psoriatic skin lesions the "palm" rule is applicable. On the scalp, the affected area the size of one palm is assumed to be 10%, the torso - 3.3%, the upper extremities - 5%, the lower extremities - 2.5% of the area of the anatomical region of the body. To calculate the total BSA, each reported percentage must be multiplied by the corresponding factor of the corresponding body region (head = 0.1, torso = 0.3, upper extremities = 0.2, lower extremities = 0.4). The resulting four percentage values (percentage of skin affected by psoriasis on the scalp, upper extremities, trunk, and lower extremities) will be summed to estimate the BSA index.

Week 60
Changes in PGA
Lasso di tempo: Week 60

The PGA is 7-point scale used in clinical trials of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).

Week 60
Changes in the intensity of itching on the visual analogue scale (VAS)
Lasso di tempo: Week 60

The intensity of itching is carried out at all visits using a visual analogue scale (VAS), where the left end of the line is 0 = no itching, the right end of the line is 10 = intense itching

Week 60
Changes in quality of life, assessed using the Dermatology Life Quality Index (DLQI)
Lasso di tempo: Week 60

The DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).

Week 60
The proportion of patients who dropped out of the study due to lack of sufficient therapeutic response
Lasso di tempo: Week 60

Treatment failure is assessed as no effect within 28 weeks (PASI response <50%)

Week 60

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Cattedra di studio: Oksana A. Markova, MD, JSC GENERIUM

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 luglio 2023

Completamento primario (Effettivo)

30 aprile 2025

Completamento dello studio (Effettivo)

26 novembre 2025

Date di iscrizione allo studio

Primo inviato

28 giugno 2024

Primo inviato che soddisfa i criteri di controllo qualità

3 luglio 2024

Primo Inserito (Effettivo)

5 luglio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

21 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi